Zavegepant and the Gepant Class for Migraine Care
Episode 36, May 07, 2021, 10:00 AM
Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Elyse Stock, MD, chief medical officer, Biohaven Pharmaceuticals, and Thomas Shiovitz, MD, director of California Neuroscience Research, to discuss the recently initiated phase 2/3 clinical trial of zavegepant, an oral CGRP-targeting agent for the prevention of migraine developed by Biohaven, as well as how the treatment fits into the gepant class, and the impact that the gepants have had on migraine care overall.
In this episode, we spoke with Elyse Stock, MD, chief medical officer, Biohaven Pharmaceuticals, and Thomas Shiovitz, MD, director of California Neuroscience Research, to discuss the recently initiated phase 2/3 clinical trial of zavegepant, an oral CGRP-targeting agent for the prevention of migraine developed by Biohaven, as well as how the treatment fits into the gepant class, and the impact that the gepants have had on migraine care overall.
Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.